Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: Latest findings and interpretations

Therapeutic Advances in Gastroenterology

Volumn 6, Issue 5, 2013, Pages 412-419

  Liu, Eric ^a   Marincola, Paula ^a   Oberg, Kjell ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Afinitor; Carcinoid; Everolimus; mTOR; NETs; Neuroendocrine; Pancreatic; RADIANT; Sunitinib; Tumor

Indexed keywords

CYTOPLASM PROTEIN; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; RAPAMYCIN; STREPTOZOCIN; SUNITINIB; TEMSIROLIMUS;

BINDING AFFINITY; DRUG BINDING; DRUG EFFICACY; GENE EXPRESSION; HAZARD RATIO; HUMAN; MULTICENTER STUDY (TOPIC); PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84883412931     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X13496970     Document Type: Article

References (43)

1. Bai X. Jiang Y. (2010) Key factors in mTOR regulation. Cell Mol Life Sci 67: 239–253.
2. Ballou L. Lin R. (2008) Rapamycin and mTOR kinase inhibitors. J Chem Biol 1: 27–36.
3. Baselga J. Campone M. Piccart M. Burris H. 3rd (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520–529.
4. Beevers C. Li F. Liu L. Huang S. (2006) Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 119: 757–764.
5. Beuvink I. Boulay A. Fumagalli S. Zilbermann F. Ruetz S. O'Reilly T. et al (2005) The mTOR inhibitor RAD 001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p 21 translation. Cell 120: 747–759.
6. Boulay A. Zumstein-Mecker S. Stephan C. Beuvink I. Zilbermann F. Haller R. et al (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD 001 correlates with prolonged inactivation of ribosomal protein S 6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64: 252–261.
7. Chiu C. Nozawa H. Hanahan D. (2010) Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 28: 4425–4433.
8. Duran I. Kortmansky J. Singh D. Hirte H. Kocha W. Goss G. et al (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95: 1148–1154.
9. Easton J. Houghton P. (2006) mTOR and cancer therapy. Oncogene 25: 6436–6446.
10. Gingras A. Raught B. Sonenberg N. (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807–826.
11. Grozinsky-Glasberg S. Shimon I. (2010) The potential role of mTOR inhibitors in the treatment of endocrine tumors. J Endocrinol Invest 33: 276–281.
12. Grunwald V. Degraffenried L. Russel D. Friedrichs W. Ray R. Hidalgo M. (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62: 6141–6145.
13. Hay N. Sonenberg N. (2004) Upstream and downstream of mTOR. Genes Dev 18: 1926–1945.
14. Hochwald S. Zee S. Conlon K. Colleoni R. Louie O. Brennan M. et al (2002) Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20: 2633–2642.
15. Jiao Y. Shi C. Edil B. de Wilde R. Klimstra D. Maitra A. et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331: 1199–1203.
16. Klimstra D. Modlin I. Coppola D. Lloyd R. Suster S. (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39: 707–712.
17. Leung R. Lang B. Wong H. Chiu J. Yat W. Shek T. et al (2013) Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy. Anticancer Agents Med Chem 13: 382–388.
18. Liu P. Cheng H. Roberts T. Zhao J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627–644.
19. Markman B. Dienstmann R. Tabernero J. (2010) Targeting the PI3K/Akt/mTOR pathway – beyond rapalogs. Oncotarget 1: 530–543.
20. Meric-Bernstam F. Gonzalez-Angulo A. (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278–2287.
21. Missiaglia E. Dalai I. Barbi S. Beghelli S. Falconi M. Della Peruta M. et al (2010) Pancreatic endocrine tumors: expression profiling evidences a role for Akt-mTOR pathway. J Clin Oncol 28: 245–255.
22. Motzer R. Escudier B. Oudard S. Hutson T. Porta C. Bracarda S. et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449–456.
23. Nakabayashi M. Werner L. Courtney K. Buckle G. Oh W. Bubley G. et al (2012) Phase II trial of RAD 001 and bicalutamide for castration-resistant prostate cancer. BJU Int 110: 1729–1735.
24. O'Donnell A. Faivre S. Burris H. 3rd Rea D. Papadimitrakopoulou V. Shand N. et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26: 1588–1595.
25. Oberstein P. Saif M. (2012) Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 6: 41–51.
26. Patel V. Marsh C. Dorsam R. Mikelis C. Masedunskas A. Amornphimoltham P. et al (2011) Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 71: 7103–7112.
27. Pavel M. Hainsworth J. Baudin E. Peeters M. Horsch D. Winkler R. et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378: 2005–2012.
28. Peng L. Schwarz R. (2013) Pancreatic neuroendocrine tumors: signal pathways and targeted therapies. Curr Mol Med 13: 333–339.
29. Podsypanina K. Lee R. Politis C. Hennessy I. Crane A. Puc J. et al (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/− mice. Proc Natl Acad Sci U S A 98: 10320–10325.
30. Rosner M. Hengstschlager M. (2008) Cytoplasmic and nuclear distribution of the protein complexes mTORC 1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC 2 components rictor and sin1. Hum Mol Genet 17: 2934–2948.
31. Sabatini D. (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729–734.
32. Serra S. Zheng L. Hassan M. Phan A. Woodhouse L. Yao J. et al (2012) The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res 72: 5683–5691.
33. Strosberg J. Gardner N. Kvols L. (2009) Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas 38: 255–258.
34. Tokunaga C. Yoshino K. Yonezawa K. (2004) mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun 313: 443–446.
35. Wan X. Harkavy B. Shen N. Grohar P. Helman L. (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932–1940.
36. Weber H. (2013) Medical treatment of neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes 20: 27–31.
37. Wullschleger S. Loewith R. Hall M. (2006) TOR signaling in growth and metabolism. Cell 124: 471–484.
38. Yao J. Hassan M. Phan A. Dagohoy C. Leary C. Mares J. et al (2008 a) One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063–3072.
39. Yao J. Lombard-Bohas C. Baudin E. Kvols L. Rougier P. Ruszniewski P. et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28: 69–76.
40. Yao J. Phan A. Chang D. Wolff R. Hess K. Gupta S. et al (2008 b) Efficacy of RAD 001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26: 4311–4318.
41. Yao J. Shah M. Ito T. Bohas C. Wolin E. van Cutsem E. et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514–523.
42. Yee K. Zeng Z. Konopleva M. Verstovsek S. Ravandi F. Ferrajoli A. et al (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12: 5165–5173.
43. Zeng Z. Sarbassov Dos D. Samudio I. Yee K. Munsell M. Ellen Jackson C. et al (2007) Rapamycin derivatives reduce mTORC 2 signaling and inhibit Akt activation in AML. Blood 109: 3509–3512.